1. |
Progress with immunomodulators promising for psoriasis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1406,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
2. |
European Commission, EMEA and FDA agree to exchange information |
|
Inpharma Weekly,
Volume &NA;,
Issue 1406,
2003,
Page 3-3
Reactions,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
3. |
Rheumatic fever: old disease needs new cures |
|
Inpharma Weekly,
Volume &NA;,
Issue 1406,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
4. |
Hepatitis B significant cost burden in Asia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1406,
2003,
Page 5-6
L Hunt,
Preview
|
|
摘要:
Hepatitis B is endemic in certain parts of Asia and is associated with high costs of management. However, the economic burden imposed on the healthcare budgets of countries such as China, Korea and Singapore has not been well assessed. At the First Asia-Pacific ISPOR*conference [Kobe, Japan; September 2003], researchers presented the results of four studies evaluating the cost burden associated with chronic hepatitis B and it complications in three countries, China, Korea and Singapore.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
5. |
Rizatriptan maximises work productivity in migraine |
|
Inpharma Weekly,
Volume &NA;,
Issue 1406,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
6. |
Decitabine active in chronic myeloid leukaemia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1406,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
7. |
Stem cell transplantation for myocardial infarction? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1406,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
8. |
Eicosapentaenoic acid can restore tamoxifen sensitivity in resistant breast cancer cells, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1406,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
9. |
Azithromycin effective in community-acquired pneumonia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1406,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
10. |
CHARM: Candesartan effective in heart failure |
|
Inpharma Weekly,
Volume &NA;,
Issue 1406,
2003,
Page 11-13
RM Poole,
Preview
|
|
摘要:
The angiotensin II receptor blocker (ARB) candesartan cilexetil is effective in the treatment of chronic heart failure (CHF), according to studies presented in a hotline session at the European Society of Cardiology (ESC) 2003 Congress [Vienna, Austria; August-September 2003] and subsequently published in theLancet.Results from CHARM, the largest clinical trial programme to evaluate the efficacy of an ARB in heart failure showed that candesartan, given in combination with standard therapy, significantly reduced the incidences of cardiovascular-related mortality and hospitalisation. Candesartan is the first drug of its class to be shown to increase survival in patients with CHF with left ventricular dysfunction, whether or not they are receiving ACE inhibitor therapy. "CHARM will influence the way that clinicians treat heart failure,"according to Professor Karl Swedberg from Göteborg University, Sweden."We cannot ignore the fact that this treatment will save lives in heart failure regardless of whether the person is taking an ACE-inhibitor or beta blocker. The benefits are also irrespective of left ventricular ejection fraction".
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|